Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH. Hadji P, et al. Among authors: spieler w. Osteoporos Int. 2012 Jul;23(7):2043-51. doi: 10.1007/s00198-011-1834-4. Epub 2011 Nov 16. Osteoporos Int. 2012. PMID: 22086310 Clinical Trial.
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V. Hadji P, et al. Among authors: spieler w. Osteoporos Int. 2012 Feb;23(2):625-33. doi: 10.1007/s00198-011-1583-4. Epub 2011 Mar 26. Osteoporos Int. 2012. PMID: 21442459 Clinical Trial.
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group. Blumsohn A, et al. Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12. Osteoporos Int. 2011. PMID: 20938767 Free PMC article. Clinical Trial.
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group. Silverman SL, et al. Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21. Osteoporos Int. 2012. PMID: 21779819 Clinical Trial.
The effects of tibolone in older postmenopausal women.
Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators. Cummings SR, et al. N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743. N Engl J Med. 2008. PMID: 18703472 Free PMC article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study.
Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C, Röther E, Spieler W, Gnann H, Wittig BM. Kleinert S, et al. Among authors: spieler w. Rheumatol Int. 2012 Sep;32(9):2759-67. doi: 10.1007/s00296-011-2033-5. Epub 2011 Aug 6. Rheumatol Int. 2012. PMID: 21822659 Free PMC article.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. McClung MR, et al. Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team. van Vollenhoven RF, et al. Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17. Ann Rheum Dis. 2018. PMID: 29343509 Clinical Trial.
17 results